Intestinal obstruction in patients receiving peptide receptor radionuclide therapy for gastroentero-pancreatic neuroendocrine tumors: potential predictors and association with overall survival

被引：0
|
作者：
Badawy, Mohamed
Johnson, Geoffrey [1 ]
Wee, Christopher [2 ]
Halfdanarson, Thorvardur R. [1 ]
Abdelrazek, Ahmad [1 ]
Packard, Ann [1 ]
Jain, Manoj
Thorpe, Matthew [1 ]
Kendi, Ayse [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Cleveland Clin, Cleveland, OH USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P439
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors
    Riff, Brian P.
    Yang, Yu-Xiao
    Soulen, Michael C.
    Pryma, Daniel A.
    Bennett, Bonita
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina R.
    Metz, David C.
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) : 845 - 850
  • [32] Quality Of Life in Patients with Neuroendocrine Gastroenteropancreatic Tumors Treated with Peptide Receptor Radionuclide Therapy
    Georgakopoulos, A.
    Liotsou, T.
    Chatziioannou, S. N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S691 - S691
  • [33] Peptide Receptor Radionuclide Therapy (PRRT) a Novel Option as Neoadjuvant Therapy for Pancreatic Neuroendocrine Tumors: A Surgical Series
    Miotto, M.
    Nessi, C.
    Cingarlini, S.
    Severi, S.
    Paganelli, G.
    Malleo, G.
    D'Onofrio, M.
    Pea, A.
    Vincenzi, S.
    Scarpa, A.
    Salvia, R.
    Landoni, L.
    NEUROENDOCRINOLOGY, 2019, 108 : 254 - 254
  • [34] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Mina M. Swiha
    Duncan E. K. Sutherland
    Golmehr Sistani
    Alireza Khatami
    Rami M. Abazid
    Amol Mujoomdar
    Daniele P. Wiseman
    Jonathan G. Romsa
    Robert H. Reid
    David T. Laidley
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
  • [35] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
  • [36] Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)
    Marco Schiavo Lena
    Stefano Partelli
    Paola Castelli
    Valentina Andreasi
    Chanel Elisha Smart
    Eleonora Pisa
    Mirco Bartolomei
    Emilio Bertani
    Giuseppe Zamboni
    Massimo Falconi
    Claudio Doglioni
    Endocrine Pathology, 2020, 31 : 119 - 131
  • [37] Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)
    Schiavo Lena, Marco
    Partelli, Stefano
    Castelli, Paola
    Andreasi, Valentina
    Smart, Chanel Elisha
    Pisa, Eleonora
    Bartolomei, Mirco
    Bertani, Emilio
    Zamboni, Giuseppe
    Falconi, Massimo
    Doglioni, Claudio
    ENDOCRINE PATHOLOGY, 2020, 31 (02) : 119 - 131
  • [38] Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor
    Kucukyurt, Selin
    Yagiz Ozogul, Yeliz
    Ercaliskan, Abdulkadir
    Kabasakal, Levent
    Eskazan, Ahmet Emre
    CANCER REPORTS, 2020, 3 (05)
  • [39] Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
    Pretot, Dominique
    Engel-Bicik, Ivette
    Kenkel, David
    Kaufmann, Philipp A.
    Treyer, Valerie
    Siebenhuner, Alexander R.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (03) : 1204 - 1217
  • [40] Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)
    Norman, A.
    Wee, C.
    Hobday, T.
    Kendi, A.
    Johnson, G.
    Thorpe, M.
    Lunn, B.
    Bach, C.
    Eiring, R.
    Halfdanarson, T.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 192 - 192
12345